LUCY LETBY CASE ROCKED AGAIN AS NEW INSULIN REPORT PUTS KEY TRIAL EVIDENCE UNDER THE MICROSCOPE

LONDON — The Lucy Letby case is facing another major challenge as new expert evidence raises fresh questions about one of the most important pieces of medical evidence used to convict the former neonatal nurse.

Letby is currently serving whole-life sentences after being convicted of murdering seven babies and attempting to murder eight others at the Countess of Chester Hospital.

Her convictions remain in force.

But behind the scenes, her legal team is continuing its fight to have the case reviewed — and the Criminal Cases Review Commission (CCRC) is now examining the material.

THE NEW REPORT FOCUSES ON INSULIN

One of the latest developments came in July 2026, when Letby’s legal team submitted a new 100-page analysis to the CCRC challenging aspects of the insulin evidence presented at trial.

The report was prepared by consultant neonatologist Neil Aiton and statistician Hilde Wilkinson-Herbots.

Among other issues, the report reportedly challenges the evidence given by prosecution insulin expert Professor Peter Hindmarsh and raises questions about alternative explanations for the babies’ laboratory results.

The report itself has not been publicly released, meaning its full contents cannot currently be independently assessed.

But its submission adds another layer to an increasingly intense scientific debate surrounding the convictions.

WHY THE INSULIN CASES MATTER

The insulin allegations involving Babies F and L were particularly significant because prosecutors argued that the infants had been deliberately poisoned.

The laboratory results were presented as evidence supporting that theory.

However, independent researchers have since questioned whether the results necessarily prove that exogenous insulin was administered.

A peer-reviewed paper published in April 2026 proposed biological mechanisms that could potentially produce unusually high insulin readings in premature infants.

Importantly, the research does not establish that Letby did not administer insulin.

Instead, it challenges whether the laboratory results alone can establish deliberate administration beyond reasonable doubt.

That distinction could become crucial if the CCRC ultimately examines whether the convictions remain safe.

AN INTERNATIONAL PANEL ALSO RAISED QUESTIONS

The insulin debate is not the only controversy.

In 2025, an international panel of neonatologists led by Dr. Shoo Lee reviewed medical evidence in the case and said it found no medical evidence of deliberate harm in the cases it examined.

That conclusion has become an important part of Letby’s legal team’s argument.

The defense says the new expert evidence demonstrates that alternative medical explanations were not adequately considered at trial.

Prosecutors and the original jury, however, considered a much broader body of evidence before Letby was convicted.

THE CCRC IS NOW REVIEWING THE CASE

Letby’s application to the CCRC was initially submitted in February 2025.

Since then, additional expert reports, submissions and defense material have been provided.

The CCRC confirmed in February 2026 that its review was underway.

But the commission has made one point extremely clear:

It does not decide whether Letby is innocent or guilty.

Its role is to determine whether there is a real possibility that a conviction may not be upheld if new evidence or arguments are referred to the appellate courts.

ANOTHER SURPRISE DEVELOPMENT

The medical evidence is not the only issue attracting attention.

Questions have also been raised about how hospital conditions, staffing problems and alternative explanations for infant collapses were considered during the original investigation.

The separate Thirlwall Inquiry has been examining events and institutional failures surrounding the Countess of Chester Hospital.

However, the inquiry is not an appeal court and cannot overturn Letby’s convictions.

Its final report is expected after the summer parliamentary recess.

NO NEW CHARGES WILL BE BROUGHT

Meanwhile, another important legal development emerged in August.

The Crown Prosecution Service confirmed that an independent review had upheld its earlier decision not to bring additional criminal charges against Letby concerning six further infants.

The review considered six alleged attempted-murder offenses and concluded that the original decision not to prosecute should stand.

That decision does not change Letby’s existing convictions.

But it closes another potential criminal avenue surrounding the wider investigation.

THE BIG QUESTION NOW

The controversy surrounding Lucy Letby has moved far beyond one courtroom.

It now involves competing interpretations of neonatal medicine, laboratory testing, statistics, hospital conditions and expert testimony.

The defense says the new evidence raises serious doubts about whether the original convictions are safe.

The convictions, however, remain legally valid.

No court has ruled that Letby was wrongly convicted.

And the CCRC has not announced a decision to refer the case back to the Court of Appeal.

WHAT HAPPENS NEXT?

The next major development could come from the CCRC.

If the commission concludes that the new evidence creates a real possibility that the convictions would not be upheld, it could refer the case to the Court of Appeal.

If it does not, Letby’s convictions will remain in place.

For now, the legal battle continues behind closed doors.

The scientific debate, meanwhile, is becoming increasingly intense.

A new insulin report. Fresh questions about expert testimony. A major review by the CCRC. And a separate inquiry examining what went wrong inside the hospital.

Lucy Letby’s convictions have not been overturned.

But the evidence surrounding one of Britain’s most controversial criminal cases is once again being placed under an extraordinary level of scrutiny.

And the next decision could determine whether the case enters another chapter — or remains exactly where it stands today.